Pharmaceutical Manufacturing Government Bids & RFPs

The bid notice states that offerors can be either a single organization with a full technology solution or a two-part team that together offers a full technology solution comprised of an antigen expression capability and a vaccine carrier formulation capability.

The bid notice states an estimated delivery schedule from 1 June 2026 to 31 May 2031.

The bid notice states this is a otice of intent to award a sole source purchase order/contract and that only one source being available to meet the governments needs.

The bid notice requires interested sources to submit a capability statement that includes management and technical data and cost information, insufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required ino gas supply.

The bid notice states The closing date for challenges is no later than 10:00 a. m. pacific, thursday 9 april 2026.

The bid notice does not specify a delivery deadline for the products.

The bid notice does not specify payment terms.

The bid notice does not specify warranty information.

The bid notice states that the VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items.

The bid notice states that offers of covered drugs including biologics that fall within 21 CFR **** will only be considered for award if the offeror has an executed MA and PPA which includes the offered NDC's on file with the VA National Acquisition Center, FSS in accordance with 38 **** H 2. Furthermore, in order to be considered for award under this solicitation, all proposed covered drug product's must be present on the offeror's FSS contract or interim agreement with an established permanent FCP associated with the offeror's FSS contract or interim agreement by this solicitation's due date and time for receipt of offers. Offers failing to meet these criteria will be rejected and receive no further consideration. Proposed biosimilar products must be biological products licensed by the FDA under 42 U. S. C. 262 and must meet all biosimilar criteria described in 42 U. S. C. 262.

The bid notice does not specify penalties.

The bid notice does not mention a site visit.

The bid notice does not mention sample submission.

The bid notice does not specify a challenge deadline.

The bid notice does not provide an estimated total value for the procurement.

The bid notice does not explicitly state a delivery deadline. Please refer to RFQ Exhibit A for delivery information.

The question deadline for this bid is Thursday, April 2, 2026, 5:00:00 PM CDT.

The bid notice states that the contract period will be for one year plus four pre-priced one year option periods. The tentative closing date for proposals is April 13, 2026. The notice does not specify a deadline for the total delivery of services beyond the contract period.

The bid notice states that the VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items.

The bid notice states that offers will be considered from all responsible sources.

The bid notice does not mention any requirement for a site visit.

The bid notice provides estimated annual usage for the items but does not state a total estimated monetary value for the contract.